Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03595683
Title Pembrolizumab and EDP1503 in Advanced Melanoma
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.